56 related articles for article (PubMed ID: 12576338)
1. Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells.
Deutsch E; Jarrousse S; Buet D; Dugray A; Bonnet ML; Vozenin-Brotons MC; Guilhot F; Turhan AG; Feunteun J; Bourhis J
Blood; 2003 Jun; 101(11):4583-8. PubMed ID: 12576338
[TBL] [Abstract][Full Text] [Related]
2. A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.
Notari M; Neviani P; Santhanam R; Blaser BW; Chang JS; Galietta A; Willis AE; Roy DC; Caligiuri MA; Marcucci G; Perrotti D
Blood; 2006 Mar; 107(6):2507-16. PubMed ID: 16293596
[TBL] [Abstract][Full Text] [Related]
3. Modeling Global Genomic Instability in Chronic Myeloid Leukemia (CML) Using Patient-Derived Induced Pluripotent Stem Cells (iPSCs).
Telliam G; Desterke C; Imeri J; M'kacher R; Oudrhiri N; Balducci E; Fontaine-Arnoux M; Acloque H; Bennaceur-Griscelli A; Turhan AG
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174060
[TBL] [Abstract][Full Text] [Related]
4. Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells.
Hiroki H; Ishii Y; Piao J; Namikawa Y; Masutani M; Honda H; Akahane K; Inukai T; Morio T; Takagi M
Sci Rep; 2023 May; 13(1):7588. PubMed ID: 37165001
[TBL] [Abstract][Full Text] [Related]
5. Modeling Blast Crisis Using Mutagenized Chronic Myeloid Leukemia-Derived Induced Pluripotent Stem Cells (iPSCs).
Imeri J; Desterke C; Marcoux P; Telliam G; Sanekli S; Barreau S; Erbilgin Y; Latsis T; Hugues P; Sorel N; Cayssials E; Chomel JC; Bennaceur-Griscelli A; Turhan AG
Cells; 2023 Feb; 12(4):. PubMed ID: 36831265
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effect of combined PI3 kinase inhibitor and PARP inhibitor treatment on BCR/ABL1-positive acute lymphoblastic leukemia cells.
Hiroki H; Akahane K; Inukai T; Morio T; Takagi M
Int J Hematol; 2023 May; 117(5):748-758. PubMed ID: 36575328
[TBL] [Abstract][Full Text] [Related]
7. Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality.
Le BV; Podszywałow-Bartnicka P; Piwocka K; Skorski T
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497275
[TBL] [Abstract][Full Text] [Related]
8. BRCA1 and TP53 codeficiency causes a PARP inhibitor-sensitive erythroproliferative neoplasm.
Lopez-Perez G; Wijayatunge R; McCrum KB; Holmstrom SR; Mgbemena VE; Ross TS
JCI Insight; 2022 Dec; 7(24):. PubMed ID: 36346676
[TBL] [Abstract][Full Text] [Related]
9. Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia-From Molecular Mechanisms to Clinical Relevance.
Alves R; Gonçalves AC; Rutella S; Almeida AM; De Las Rivas J; Trougakos IP; Sarmento Ribeiro AB
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638304
[TBL] [Abstract][Full Text] [Related]
10. Should the BCRA1/2-mutations healthy carriers be valid candidates for hematopoietic stem cell donation?
Fresa A; Sica S
Hered Cancer Clin Pract; 2021 Apr; 19(1):22. PubMed ID: 33794974
[TBL] [Abstract][Full Text] [Related]
11. SNPs in lncRNA Regions and Breast Cancer Risk.
Suvanto M; Beesley J; Blomqvist C; Chenevix-Trench G; Khan S; Nevanlinna H
Front Genet; 2020; 11():550. PubMed ID: 32714364
[TBL] [Abstract][Full Text] [Related]
12. Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes.
Stetka J; Gursky J; Liñan Velasquez J; Mojzikova R; Vyhlidalova P; Vrablova L; Bartek J; Divoky V
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32272770
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update.
Bavaro L; Martelli M; Cavo M; Soverini S
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817512
[TBL] [Abstract][Full Text] [Related]
14. TET2 Function in Hematopoietic Malignancies, Immune Regulation, and DNA Repair.
Feng Y; Li X; Cassady K; Zou Z; Zhang X
Front Oncol; 2019; 9():210. PubMed ID: 31001476
[TBL] [Abstract][Full Text] [Related]
15. Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML).
Gentil M; Hugues P; Desterke C; Telliam G; Sloma I; Souza LEB; Baykal S; Artus J; Griscelli F; Guerci A; Johnson-Ansah H; Foudi A; Bennaceur-Griscelli A; Turhan AG
PLoS One; 2018; 13(8):e0200923. PubMed ID: 30091999
[TBL] [Abstract][Full Text] [Related]
16. T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR/Cas9 system.
Tamai M; Inukai T; Kojika S; Abe M; Kagami K; Harama D; Shinohara T; Watanabe A; Oshiro H; Akahane K; Goi K; Sugihara E; Nakada S; Sugita K
Sci Rep; 2018 Jul; 8(1):9966. PubMed ID: 29967475
[TBL] [Abstract][Full Text] [Related]
17. PARP1 inhibitor eliminated imatinib-refractory chronic myeloid leukemia cells in bone marrow microenvironment conditions.
Podszywalow-Bartnicka P; Maifrede S; Le BV; Nieborowska-Skorska M; Piwocka K; Skorski T
Leuk Lymphoma; 2019 Jan; 60(1):262-264. PubMed ID: 29932782
[No Abstract] [Full Text] [Related]
18. Taking a Bad Turn: Compromised DNA Damage Response in Leukemia.
Nilles N; Fahrenkrog B
Cells; 2017 May; 6(2):. PubMed ID: 28471392
[TBL] [Abstract][Full Text] [Related]
19. DNA damage response and hematological malignancy.
Takagi M
Int J Hematol; 2017 Sep; 106(3):345-356. PubMed ID: 28374143
[TBL] [Abstract][Full Text] [Related]
20. Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression.
Rebechi MT; Pratz KW
Leuk Lymphoma; 2017 Sep; 58(9):1-11. PubMed ID: 28278729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
